Table 2.
First-line chemotherapy regimens administered in the two groups of patients
| Group A | N. patients | Group B | N. patients |
|---|---|---|---|
| PELF | 138 (64 %) | CDDP + 5-FU | 86 (41 %) |
| ECF | 12 (5.5 %) | FOLFOX | 43 (21 %) |
| CDDP + 5-FU + MMC | 50 (23 %) | 5-FU + MMC | 56 (27 %) |
| TCF | 12 (5.5 %) | FOLFIRI | 14 (6.7 %) |
| FAM | 4 (2 %) | CDDP + docetaxel | 9 (4 %) |
| IROX | 1 (0.3 %) |
PELF (cisplatin, epirubicin, 5-FU and leucovorin), ECF (epirubicin, cisplatin and 5-FU), TCF (docetaxel, cisplatin, 5-FU), MMC (mytomicin C), FAM (5-FU, adriamycin, cyclofosfamid) CDDP (cisplatin), FOLFIRI (5-FU, leucovorin, irinotecan, irinotecan), IROX (irinotecan, oxaliplatin)